From March 21 to 23, 2026, the 23rd China International Clinical Laboratory Medicine and Blood Transfusion Instruments & Reagents Expo (CACLP) successfully concluded at the Xiamen International Expo Center, China. As a domestic innovator engaged in original research in gene sequencing technology, Cygnus Biosciences (Beijing) Co., Ltd. presented its full range of gene sequencers and integrated solutions, engaging in in-depth exchanges with industry peers and professionals.
At this year’s exhibition, Cygnus Bio systematically showcased its Product Line S (GS100/GS200) and Product Line P (GP1000/GP1000X) gene sequencers, which cater to diverse application scenarios. The display highlighted the company’s breakthroughs in core underlying technologies and achievements in industrialization. Leveraging proprietary technologies including fluorogenic sequencing technology, ECC error correction coding, Attoseal, and LumoSeq sequencing chemistry, Cygnus Bio has established a fully independent intellectual property technology system. Its products, distinguished by high accuracy, rapid sequencing, flexible throughput, and controllable costs, attracted numerous experts and distributor representatives for on-site discussions. Notably, the desktop sequencers in Product Line S stood out for their high compatibility and flexibility, drawing keen interest for clinical testing and public health applications, while the high-throughput platform of Product Line P demonstrated strong capabilities in scientific research services and multi-omics applications.
At the booth, the Cygnus Bio team held in-depth discussions with visitors on technology applications and potential cooperation models. As gene sequencing technology penetrates a growing number of application scenarios, market demand for fully patented, cost-effective gene sequencers continues to rise. Many visitors expressed strong recognition of Cygnus Bio’s commitment to original innovation, affirming that the company effectively controls costs while ensuring data quality, delivering highly accessible tools that address core customer needs.
Cygnus Bio has long focused on the independent research, development, manufacturing, and commercialization of gene sequencers, committed to advancing the accessibility and affordability of gene sequencing technology. CACLP 2026 served not only as a platform to showcase the company’s innovative achievements but also as a venue for mutual inspiration with industry counterparts.
Moving forward, as a representative of domestic original research, Cygnus Bio will continue to drive underlying innovation in gene sequencing technology, building a solid and reliable technical platform to explore the mysteries of life and improve public health. Building on its core technological strengths, the company will further optimize its product portfolio and accelerate the implementation of solutions across more application scenarios. Cygnus Bio looks forward to collaborating with experts, scholars, and partners to jointly expand the depth and breadth of sequencing technology applications.
